Table 5.
Distribution of targets for antibodies and Fc fusion proteins by major indications in therapeutic areas and location*
| Therapeutic area | Antibodies binding to target types | Totals | |||
|---|---|---|---|---|---|
| Cell-bound targets** | Soluble targets | GPCRs or multi-pass receptors on cells | Infectious agents and toxins | ||
| Oncology | 143 | 26 | 5 | 1 | 175 |
| Inflammation and autoimmune diseases (including asthma, but excluding MS) | 52 | 42 | 1 | 0 | 95 |
| Ophthalmological diseases | 1 | 7 | 0 | 0 | 8 |
| Infectious diseases | 2 | 0 | 1 | 11 infectious agents; 3 toxins | 17 |
| Neurobiology diseases including MS | 7 | 5 | 0 | 0 | 12 |
| Cardiovascular and metabolism | 9 | 1 | 4 | 0 | 14 |
| Pain and migraine | 3 | 2 | 1 | 0 | 6 |
| Blood homeostasis | 3 | 17 | 0 | 0 | 20 |
| Bone and muscle | 2 | 2 | 0 | 0 | 4 |
| Totals and percent of total | 222 (~63%) | 102 (~29%) | 12 (~3.4%) | 15 (~4.3%) | 351 |
Abbreviations: Fc, fragment crystallizable; MS, multiple sclerosis; GPCR, G-protein coupled receptor
* These numbers add up to more than the 328 unique targets noted in Table 4 because several targets have major indications in multiple therapeutic areas (e.g., anti-vascular endothelial growth factor [VEGF] antibodies with major indications in both oncology and ophthalmology)
** Mostly single-pass membrane targets, either as monomeric cell-bound proteins, homodimeric receptors, or heterodimeric receptors